Citizens reiterates Blend Labs stock rating after investor meetings

Citizens reiterated a Market Outperform on Blend Labs but cut its price target from $7.00 to $5.00 after reviewing Q4 2025 results. Revenue modestly beat at $32.4M vs $31.78M consensus while non-GAAP EPS from continuing operations was $0.00 in line with estimates; the stock trades at $1.64 (market cap $421.7M) and is down roughly 56–58% over the past 12 months. Analyst targets range $2.00–$5.25 and InvestingPro’s fair value is $1.58, implying the shares may be slightly overvalued at current levels.

Analysis

Blend sits at the intersection of secular digitization and cyclical origination volumes, which creates a high convexity payoff: modest macro improvement can materially lift ARR and NRR, while a prolonged pullback in lender spend or origination activity can compress revenue rapidly because professional services/implementation are more lumpy than true recurring SaaS. Incumbent platforms with deep bank relationships and balance-sheet scale (strategic acquirers) have optionality to win by bundling compliance, data and execution services — that raises takeover value but also intensifies competitive pricing pressure on smaller pure-play vendors.

Second-order effects are underappreciated: persistent rate or risk-premium volatility drives lenders to re-prioritize tech budgets toward efficiency (automation, process consolidation), which favors vendors that can demonstrably cut FTE or cycle time versus those dependent on origination volumes. Conversely, if geopolitical-driven rate fears normalize only slowly, a multi-quarter hangover in originations would push managements to lean into non-core monetization (data/licensing) or accelerate M&A talks — both visible within 3–9 months.

Key tails to watch: (1) customer concentration roll-offs and contract renewals (binary within the next two quarters), (2) regulatory/data privacy incidents that would increase switching costs and slow new sales, and (3) a meaningful uptick in multi-product deals (deposits/consumer lending) which would materially re-rate gross retention. For investors, asymmetric option structures and relative-value pairs are the most efficient ways to express a view while capping downside given execution risk and timing uncertainty.

Key Decisions for Investors

• Pair trade (6–12 months): Long ICE (Intercontinental Exchange) / Short BLND, equal notional. Thesis: ICE’s scale and cross-sell into mortgage workflows should outperform a smaller, execution-risky pure-play if origination volumes stay depressed. Target relative outperformance 15–25%; set a hard stop if the pair moves against you by 6% absolute or if BLND reports two consecutive quarters of accelerating ARR/NRR.
• Asymmetric long (9–12 months): Buy long-dated BLND call spread (limit position to 1–2% portfolio). Use a debit spread financed by selling shorter-dated calls to reduce cost. Risk = premium paid; reward = aim for 3x premium if management shows durable ARR expansion or a strategic bid emerges.
• Event hedge (3–6 months): Buy BLND puts sized to cover ~50% of an existing equity exposure ahead of the next earnings/ARR print. If misses occur, puts can return 3–6x; if not, the premium is the cost of insurance — acceptable given binary downside risks.
• Defensive alternate (6–12 months): Overweight larger mortgage software incumbents (e.g., ICE) outright with protective puts if worried about macro. Target absolute return 10–20% capturing consolidation and share gains; cap downside using 3–6 month protective options.